Financial Data and Key Metrics Changes - The company reported a strong finish to 2025, achieving underlying revenue growth of 5.3% and free cash flow of $840 million, a 52.5% increase year-on-year [1][3] - Trading profit for the full year was $1.2 billion, reflecting a 160 basis points margin expansion to 19.7% [17][20] - Adjusted earnings per share grew by 21% to $1.02, driven by a $500 million share buyback [18][19] Business Line Data and Key Metrics Changes - Orthopedics grew by 5.1%, Sports Medicine and ENT by 5.2%, and Advanced Wound Management by 5.6%, all on an underlying basis [15][16] - The joint repair business surpassed $1 billion in revenue for the first time, driven by products like REGENETEN and Q-FIX [11][12] - Advanced Wound Management grew 2.8% in Q4, with Advanced Wound Care growing 4.4% [13][14] Market Data and Key Metrics Changes - U.S. growth was 5.6%, other established markets 7.2%, and emerging markets 6.4%, with underlying growth excluding China at 7.2% [7][16] - The company expects continued growth in orthopedics, sports medicine, and Advanced Wound Management, particularly in AWC and AWD [27][28] Company Strategy and Development Direction - The company is transitioning to a new RISE strategy aimed at accelerating growth and improving returns, building on the previous 12-Point Plan [4][31] - The acquisition of Integrity Orthopaedics is expected to enhance the sports medicine portfolio and drive growth in biomechanical repair [33][34] - The company plans to increase R&D investment and maintain a robust product launch pipeline, with expectations of launching 16 new products in 2026 [43][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving around 6% organic revenue growth in 2026, with trading profit growth expected to be around 8% [20][29] - The impact of China VBP on joint repair is expected to be less significant moving forward, with management anticipating a bounce in sports business in China [72][75] - The company aims to maintain a focus on organic growth and capital allocation towards high-value clinical segments [68][69] Other Important Information - The company achieved a 15-fold increase in free cash flow and a 170 basis points increase in ROIC from 6.6% to 8.3% [6][25] - The company expects to face extraordinary headwinds in 2026, including inventory revaluation and changes to reimbursement in the U.S. AWM business [20][21] Q&A Session Summary Question: Can you break down revenue guidance for 2026 and expectations for market growth? - Management indicated that 2026 revenue growth is expected to be around 6%, with contributions from all business units and innovation driving growth [48][49] Question: What is the expected phasing of revenue growth through the quarters? - Management expects Q1 to be softer due to one fewer trading day, with growth in the first half around 4.5%-5% and stronger growth in Q3 and Q4 [53][54] Question: What is the outlook for joint repair in China? - Management confirmed that joint repair growth in China has annualized, and they expect a bounce in sports business while AET and ENT will have a limited negative impact [64][75]

Financial Performance - The company reported a strong finish to 2025, achieving underlying revenue growth of 5.3% and free cash flow of $840 million, a 52.5% increase year-on-year [1][3][15] - Trading profit for the full year was $1.2 billion, reflecting a 160 basis points margin expansion to 19.7% [17][20] - Adjusted earnings per share grew by 21% to $1.02, driven by a $500 million share buyback [18][19] Business Unit Performance - Orthopedics grew 7.9% on an underlying basis, with strong performance in hips and trauma, while U.S. knee growth improved following the launch of LEGION MS [7][8][10] - Sports medicine and ENT grew 7.3%, with joint repair surpassing $1 billion in revenue for the first time, driven by REGENETEN and Q-FIX [11][12] - Advanced Wound Management grew 2.8%, with Advanced Wound Care growing 4.4% [13][15] Market Performance - U.S. growth was 5.6%, with other established markets at 7.2% and emerging markets at 6.4% [7] - Excluding China, underlying growth was 7.2%, indicating strong performance across various regions [16] Company Strategy and Industry Competition - The company is transitioning to a new RISE strategy aimed at accelerating growth and improving returns, building on the previous 12-Point Plan [4][31] - The acquisition of Integrity Orthopaedics is expected to enhance the sports medicine portfolio and drive growth in biomechanical repair [33][35] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in achieving around 6% organic revenue growth for 2026, with trading profit growth expected to be around 8% [20][29] - The impact of China VBP on joint repair is expected to be less significant moving forward, with management anticipating a bounce in sports business in China [72][75] Other Important Information - The company achieved a 15-fold increase in free cash flow and a 170 basis points increase in ROIC to 8.3% [6][25] - The company plans to maintain a dividend ratio of 35%-40% and consider buybacks subject to leverage targets [27] Q&A Session Summary Question: Can you break down revenue guidance for 2026 and expectations for market growth? - Management indicated that 2026 revenue growth is expected to be around 6%, with innovation contributing significantly to this growth [48][49] Question: What is the outlook for joint repair in China? - Management confirmed that joint repair growth in China has annualized, and the impact of VBP will be less significant moving forward [64][75] Question: How does M&A impact bottom line growth? - Management emphasized that M&A, such as the acquisition of Integrity, is aimed at scaling in areas of strength and is expected to be accretive in the long term [68][69]

医药生物行业周报 药辅行业迈入成熟期，关注医药辅料优 势企业 2026 年 03 月 02 日 【行情回顾】 【本周观点】 【风险提示】 医药行业政策风险；研发进展不及预期风险；业绩不及预期风险 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：何玮 证书编号：S1160517110001 证券分析师：崔晓倩 证书编号：S1160525080001 相对指数表现 -10% -2% 6% 14% 22% 30% 2025/3 2025/9 2026/3 医药生物 沪深300 相关研究 《"小而美"药辅行业迎来产业升级》 2026.02.24 《ADC 商业化进程提速，本土创新药企多 路径布局产能》 2026.02.09 《《药品管理法实施条例》全面修订，推动 医药产业创新与监管升级》 2026.02.03 《医药零售高质量发展政策发布，行业有 望加速整合利好龙头》 2026.01.27 《J.P. Morgan 健康大会召开，中国创新药 企扬帆出海》 2026.01.20 行 业 研 究 / 医 药 生 物 / 证 券 研 究 报 告 本周(2026/02/23-2026/02/27，下同） ...

Investment Rating - The report does not explicitly provide an investment rating for the medical device industry. Core Insights - The medical device industry is experiencing continuous growth globally, driven by advancements in technology, materials, and concepts, which enhance product functionality and precision [6][32]. - The industry plays a crucial role in improving healthcare services and resource allocation, significantly impacting accessibility and equity in medical care [6][32]. - The report emphasizes the importance of ESG (Environmental, Social, and Governance) principles, highlighting that adherence to these standards can enhance corporate image and drive sustainable development within the industry [7][56]. Summary by Sections Chapter 1: Overview of the Medical Device Industry - The upstream segment includes raw material supply and technology research and development, which are foundational for medical device production [19][20]. - The midstream segment focuses on product design, manufacturing, marketing, and distribution, emphasizing the need for compliance with regulatory standards [20][24]. - The downstream segment pertains to the application of medical devices in various healthcare settings, where performance, safety, and user experience are critical [29][30]. Chapter 2: ESG Development in the Medical Device Industry - The report discusses the current state of ESG information disclosure, noting that the healthcare sector has a disclosure rate of 39%, slightly below the average [56][57]. - It highlights the need for improved transparency and accountability in ESG reporting, as many companies focus on achievements while neglecting potential risks [58]. - The report outlines various domestic and international policies that guide the medical device industry towards sustainable practices, including regulations on waste management and product safety [59][62]. Chapter 3: ESG Practice Cases in the Medical Device Industry - The report presents case studies of leading companies in the medical device sector, showcasing their ESG practices and contributions to sustainable development [7][56]. - It emphasizes the importance of integrating ESG principles into corporate strategies to enhance competitiveness and address societal expectations [58][59].

| 行业基本情况 | | | | --- | --- | --- | | 收盘点位 | | 8323.7 | | 52 | 周最高 | 9323.49 | | 52 | 周最低 | 6876.88 | 行业相对指数表现 证券研究报告：医药生物|行业周报 发布时间：2026-03-02 行业投资评级 强于大市|维持 -8% -4% 0% 4% 8% 12% 16% 20% 24% 2025-03 2025-05 2025-07 2025-10 2025-12 2026-02 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:陈灿 SAC 登记编号:S1340525070001 Email:chencan@cnpsec.com 近期研究报告 《黎明已至，国产争先》 - 2026.02.27 医药生物行业报告 （2026.02.23-2026.02.27） 手术机器人行业或出台收费标准，龙头公司有望迎 加速发展 ⚫ 本周主题 手术机器人行业或出台收费标准，龙头公司有望迎加速发展 ...

沪深两指小幅低开后迅速上涨，沪指在零轴附近保持小幅震荡走势， 深成指走势相对更弱。2 月 27 日下午开盘后，两指再度走出一波上涨， 随后保持震荡至收盘。最终沪指收涨 0.39%，深成指收跌 0.06%。创业 板指和科创 50 指数表现相对弱势，分别下跌 1.04%、上涨 0.15%。两 市成交量较前一交易日基本持平。 贵金属相关板块再度成为热点，同时电力产业链部分板块同样保持了 一定热度。两者的上涨逻辑与前几日并无太大变化，其中贵金属仍主 要受国际局势变化影响，而电力产业链则主要受 AI 发展需求推动。短 期内相关原因难以迅速消失，故仍存在博弈机会。 短期市场或延续震荡，需关注一季度政策窗口期及年报、季报业绩反 馈。中长期看，国际局势波动及 AI 产业溢出仍是市场主要关注方向。 操作方面，建议关注相对涨幅较低、估值合理的绩优蓝筹。 每日市场观察 2026 年 3 月 2 日 【今日关注】 【市场回顾】 市场概况：2 月 27 日，沪指 2 月累计涨 1.09%，呈现"冲高后窄幅震 荡"的走势，月线斩获 3 连阳。深成指累计涨 2.04%，创业板指累计跌 1.08%。 【资金面】 主力资金流向：2 月 27 ...

证券研究报告 策略 PPI 上行如何影响 AH 权益？ 需求拉动型通胀：由于内生需求回暖推动价格上行，全产业链利润扩张，风 险偏好提升，行业轮动呈现明显的上游->大金融->消费的顺序，回测上看， 非金属材料、能源金属、乘用车、光伏设备、其他电源设备、玻璃玻纤等板 块主要受益，消费电子、专业服务、一般零售、厨卫电器、通信服务等板块 可能受损。 2026 年 3 月 02 日│中国内地 专题研究 宏观视角，PPI 同比有望于 5-6 月转正 考虑到 PPI 中石油化工相关商品价格、CPI 中运输和与能源相关性较高的分 项或表现强于此前预期。此外，随着 AI 投资相关需求以及外需走强，叠加 国内"反内卷"政策的稳步推进，对 PPI 波动率贡献较为显著的黑色系、有 色系上游商品价格有望延续温和回升态势，中下游（光伏设备、汽车等）价 格亦有望企稳，共同推动 PPI 指标同比降幅收窄。华泰宏观团队预测中国 PPI 或将在今年 5-6 月转正，为 2022 年 10 月来首次；2026 全年平均 PPI 或将从去年的-2.6 回升至+0.1%，而今年年底 PPI 可能达到 1%左右（《PPI 何时转正?》2026 年 3 ...

重点关注 Q1 业绩预期、积极把握主题机会；手术机器人专题：政 策打通商业化瓶颈、千亿市场驶向发展快车道 医药生物 证券研究报告/行业定期报告 2026 年 03 月 02 日 -医药生物行业 3 月月报 | | | | | | 简称 | 股价 | | | EPS | | | | | PE | | | 评级 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 分析师：祝嘉琦 | | | （元） | 2023A | 2024A | 2025E | 2026E | 2027E | 2023A | 2024A | 2025E | 2026E | 2027E | | | 执业证书编号：S0740519040001 | | 药明生物 三生国健 | 40.22 | 0.82 | 0.81 | 0.96 | 1.17 | 1.47 | 48.95 | 49.59 | 42.00 | 34.37 | 27.42 | 买入 | | | | | 59.38 | 0.48 | 1.14 | 4 ...

Core Insights - The report emphasizes the potential for investment opportunities in commodities driven by geopolitical tensions, particularly in the Middle East, which may lead to rising prices for oil and precious metals in 2026 [2][5][6] - The A-share market is expected to experience short-term volatility due to geopolitical factors, but will likely refocus on domestic fundamentals and policy expectations in the medium term [3][15] - The report highlights a significant investment in AI applications by major domestic internet companies, indicating a competitive landscape focused on user habit formation and commercial viability [9][12] Market Overview - The report lists a "March Gold Stock Portfolio" featuring companies such as Poly Real Estate Group, CITIC Hanzhong, and Mindray Medical, indicating a focus on sectors like real estate, transportation, and healthcare [1][7] - The A-share market indices showed mixed performance, with the Shanghai Composite Index closing at 4162.88, up 0.39%, while the Shenzhen Component Index fell by 0.06% [1] - The report notes that the steel industry performed well, with a 3.37% increase, while sectors like construction materials and telecommunications saw declines [1] Commodity Insights - The report anticipates that geopolitical events will significantly impact oil and certain petrochemical product prices, with a focus on the implications of the closure of the Strait of Hormuz [5][29] - It is projected that Brent crude oil prices could exceed $80 per barrel due to potential supply disruptions from Iran, with historical comparisons to the 2022 Ukraine conflict [5][29] - The chemical industry is advised to focus on low-valuation leading companies and sectors benefiting from price increases under the "anti-involution" policy [28][33] AI Industry Developments - Major domestic internet companies invested over 4.5 billion yuan in promoting AI applications during the Spring Festival, marking a shift towards practical applications and user engagement [9][12] - The report highlights the rapid evolution of domestic AI models, with significant advancements in performance and market application, indicating a dual development path towards general models and vertical industry applications [10][12] - Concerns about AI replacing human jobs are noted, but the report emphasizes that current AI capabilities are more about enhancement rather than replacement [11][12] Investment Recommendations - The report suggests focusing on companies in the AI sector and those involved in the development of general models and industry-specific AI agents, such as MINIMAX-WP and iFLYTEK [13][12] - It also recommends monitoring traditional chemical leaders that are adapting to new materials and benefiting from improving industry conditions [33]

晨会纪要（R3） 晨会纪要 2026 年 03 月 02 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 4162.88 | 0.39 | | 深证成指 | 14495.09 | -0.06 | | 创业板指 | 3310.30 | -1.04 | | 科创 50 | 1488.02 | 0.15 | | 北证 50 | 1537.13 | -0.50 | | 沪深 300 | 4710.65 | -0.34 | 上证指数-沪深 300 走势图 -8% 2% 12% 22% 32% 2025-02 2025-05 2025-08 2025-11 上证指数 沪深300 | 何晨 | 分析师 | | --- | --- | | 执业证书编号:S0530513080001 | | | hechen@hnchasing.com | | | 周舒鹏 | 研究助理 | zhoushupeng@hnchasing.com 晨会聚焦 一、财信研究观点 【债券研究】债券市场综述 二、重要财经资讯 【宏观经济】中共中央政治局召开会议，讨论"十五五"规 ...